相似文献
1
How accurate is ceftriaxone at predicting susceptibility of enterobacterales isolates to oral higher-generation cephalosporins?
Antimicrob Agents Chemother. 2025 Feb 13;69(2):e0138724. doi: 10.1128/aac.01387-24. Epub 2024 Dec 31.
2
Surrogate testing of oral third-generation cephalosporin susceptibility to common uropathogens.
Diagn Microbiol Infect Dis. 2021 Apr;99(4):115299. doi: 10.1016/j.diagmicrobio.2020.115299. Epub 2021 Jan 15.
3
Re-evaluation of penicillin and ceftriaxone MIC results to predict susceptibility to the oral cephalosporin, cefpodoxime, in clinical isolates from the United States according to CLSI guidelines (2019-2021).
J Clin Microbiol. 2025 Jun 24:e0002725. doi: 10.1128/jcm.00027-25.
4
Antibacterial activity of cefpodoxime in comparison with cefixime, cefdinir, cefetamet, ceftibuten, loracarbef, cefprozil, BAY 3522, cefuroxime, cefaclor and cefadroxil.
Infection. 1991 Sep-Oct;19(5):353-62. doi: 10.1007/BF01645369.
5
Evaluation of cefazolin as a surrogate marker for cefpodoxime susceptibility for urinary tract isolates.
J Med Microbiol. 2015 Oct;64(10):1170-1173. doi: 10.1099/jmm.0.000142. Epub 2015 Jul 23.
6
Molecular epidemiology of β-lactamases in ceftriaxone-resistant Enterobacterales bloodstream infections in the mid-Atlantic United States.
Antimicrob Agents Chemother. 2025 Mar 5;69(3):e0125824. doi: 10.1128/aac.01258-24. Epub 2025 Jan 27.
7
In-vitro activity of oral third-generation cephalosporins plus clavulanate against ESBL-producing Enterobacterales isolates from the MERINO trial.
Int J Antimicrob Agents. 2023 Aug;62(2):106858. doi: 10.1016/j.ijantimicag.2023.106858. Epub 2023 May 19.
8
Clinical outcomes of phenotype-guided treatment in group D carbapenemase-producing bacteremia.
Microbiol Spectr. 2025 Jul;13(7):e0027325. doi: 10.1128/spectrum.00273-25. Epub 2025 May 27.
9
Influence of penicillin/amoxicillin non-susceptibility on the activity of third-generation cephalosporins against Streptococcus pneumoniae.
Eur J Clin Microbiol Infect Dis. 2008 Jan;27(1):75-80. doi: 10.1007/s10096-007-0402-5. Epub 2007 Oct 18.
10
Worldwide susceptibility rates of Neisseria gonorrhoeae isolates to cefixime and cefpodoxime: a systematic review and meta-analysis.
PLoS One. 2014 Jan 31;9(1):e87849. doi: 10.1371/journal.pone.0087849. eCollection 2014.
引用本文的文献
1
Navigating the Muddled Middle: A Case-Based Exploration of Oral β-Lactams for Systemic Gram-Negative Infections.
Open Forum Infect Dis. 2025 Sep 3;12(9):ofaf435. doi: 10.1093/ofid/ofaf435. eCollection 2025 Sep.
本文引用的文献
1
Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections.
Clin Infect Dis. 2024 Aug 7. doi: 10.1093/cid/ciae403.
2
Ceftriaxone Versus Cefazolin Susceptibility as a Surrogate Marker for Cefpodoxime Susceptibility in Enterobacterales.
Open Forum Infect Dis. 2024 Jul 3;11(7):ofae377. doi: 10.1093/ofid/ofae377. eCollection 2024 Jul.
3
Early Switch From Intravenous to Oral Antibiotics for Patients With Uncomplicated Gram-Negative Bacteremia.
JAMA Netw Open. 2024 Jan 2;7(1):e2352314. doi: 10.1001/jamanetworkopen.2023.52314.
4
Transition to Oral Antibiotic Therapy for Hospitalized Adults With Gram-Negative Bloodstream Infections.
JAMA Netw Open. 2024 Jan 2;7(1):e2349864. doi: 10.1001/jamanetworkopen.2023.49864.
5
Is Carbapenem Therapy Necessary for the Treatment of Non-CTX-M Extended-Spectrum β-Lactamase-Producing Enterobacterales Bloodstream Infections?
Clin Infect Dis. 2024 May 15;78(5):1103-1110. doi: 10.1093/cid/ciad703.
6
Optimizing the Management of Uncomplicated Gram-Negative Bloodstream Infections: Consensus Guidance Using a Modified Delphi Process.
Open Forum Infect Dis. 2021 Oct 11;8(10):ofab434. doi: 10.1093/ofid/ofab434. eCollection 2021 Oct.
7
Variability in oral antibiotic step-down therapy in the management of Gram-negative bloodstream infections.
Int J Antimicrob Agents. 2021 Dec;58(6):106451. doi: 10.1016/j.ijantimicag.2021.106451. Epub 2021 Oct 20.
8
Clinical considerations for oral beta-lactams as step-down therapy for Enterobacteriaceae bloodstream infections.
Expert Opin Pharmacother. 2019 Jun;20(8):903-907. doi: 10.1080/14656566.2019.1594774. Epub 2019 Mar 25.
9
A Primer on AmpC β-Lactamases: Necessary Knowledge for an Increasingly Multidrug-resistant World.
Clin Infect Dis. 2019 Sep 27;69(8):1446-1455. doi: 10.1093/cid/ciz173.
10
Association of 30-Day Mortality With Oral Step-Down vs Continued Intravenous Therapy in Patients Hospitalized With Enterobacteriaceae Bacteremia.
JAMA Intern Med. 2019 Mar 1;179(3):316-323. doi: 10.1001/jamainternmed.2018.6226.
Zotero 插件